US6767901B1 - Ciclesonide contained pharmaceutical composition for application to mucosa - Google Patents

Ciclesonide contained pharmaceutical composition for application to mucosa Download PDF

Info

Publication number
US6767901B1
US6767901B1 US10/110,629 US11062902A US6767901B1 US 6767901 B1 US6767901 B1 US 6767901B1 US 11062902 A US11062902 A US 11062902A US 6767901 B1 US6767901 B1 US 6767901B1
Authority
US
United States
Prior art keywords
application
pharmaceutical composition
mucosa
water
mucosa according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime, expires
Application number
US10/110,629
Inventor
Atsuhiro Nagano
Yoshihisa Nishibe
Kazuya Takanashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Covis Pharma GmbH
Nycomed Germany Holding GmbH
Original Assignee
Altana Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
US case filed in Indiana Southern District Court litigation Critical https://portal.unifiedpatents.com/litigation/Indiana%20Southern%20District%20Court/case/1%3A12-cv-01073 Source: District Court Jurisdiction: Indiana Southern District Court "Unified Patents Litigation Data" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.
First worldwide family litigation filed litigation https://patents.darts-ip.com/?family=17856327&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US6767901(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Altana Pharma AG filed Critical Altana Pharma AG
Assigned to BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH reassignment BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NISHIBE, YOSHIHISA, NAGANO, ATSUHIRO, TAKANASHI, KAZUYA
Assigned to ALTANA PHARMA AG reassignment ALTANA PHARMA AG CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH
Assigned to ALTANA PHARMA AG reassignment ALTANA PHARMA AG CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH
Application granted granted Critical
Publication of US6767901B1 publication Critical patent/US6767901B1/en
Assigned to NYCOMED GMBH reassignment NYCOMED GMBH CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: ALTANA PHARMA AG
Assigned to TAKEDA GMBH reassignment TAKEDA GMBH CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: NYCOMED GMBH
Assigned to TAKEDA GMBH reassignment TAKEDA GMBH CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: NYCOMED GERMANY HOLDING GMBH
Assigned to NYCOMED GERMANY HOLDING GMBH reassignment NYCOMED GERMANY HOLDING GMBH MERGER (SEE DOCUMENT FOR DETAILS). Assignors: NYCOMED ASSET MANAGEMENT GMBH
Assigned to NYCOMED ASSET MANAGEMENT GMBH reassignment NYCOMED ASSET MANAGEMENT GMBH MERGER (SEE DOCUMENT FOR DETAILS). Assignors: TAKEDA GMBH
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TAKEDA GMBH
Assigned to COVIS PHARMA B.V. reassignment COVIS PHARMA B.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ASTRAZENECA AB
Assigned to CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT reassignment CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COVIS PHARMA B.V.
Assigned to CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT reassignment CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COVIS PHARMA B.V.
Assigned to COVIS PHARMA B.V. reassignment COVIS PHARMA B.V. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Adjusted expiration legal-status Critical
Assigned to COVIS PHARMA GMBH reassignment COVIS PHARMA GMBH BUSINESS TRANSFER AND CONTRIBUTION AGREEMENT Assignors: COVIS PHARMA B.V.
Assigned to CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT reassignment CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COVIS PHARMA GMBH
Assigned to COVIS PHARMA GMBH reassignment COVIS PHARMA GMBH RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: CAPITAL ONE, NATIONAL ASSOCIATION
Assigned to COVIS PHARMA B.V. reassignment COVIS PHARMA B.V. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: CAPITAL ONE, NATIONAL ASSOCIATION
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a pharmaceutical composition for application to the mucosa to be used in drug therapy comprising a water-insoluble and/or water-low soluble substance, ciclesonide, and an aqueous medium, and having an osmotic pressure of less than 290 mOsm.
  • the present invention relates to a pharmaceutical composition for application to the mucosa comprising a water-insoluble and/or water-low soluble substance, ciclesonide, and an aqueous medium, and having an osmotic pressure of less than 290 mOsm, that is superior to conventional pharmaceutical compositions for application to the mucosa, due to ciclesonide retentivity and high ciclesonide permeability to the submucosa and the blood at the mucosa.
  • the mucosa as a method of drug therapy has been recognized as a useful means of medication for such reasons as (1) it permits direct application to the affected area for diseases of local areas such as nasal mucosa, oral mucosa, and vaginal mucosa, (2) its immediate effects for systemic diseases can be expected as in the case of a nasal spray to the nasal mucosa and a suppository to the rectal mucosa, and (3) its application is easy compared to injection, as represented by an oral drug targeted at the intestinal mucosa, and the like.
  • pharmaceutical preparations for application to the mucosa have already been commercially available due to reason (1) in the case of nasal sprays for treatment of allergic rhinitis, and due to reason (2) in the case of suppositories to alleviate pain.
  • Saunders et al. (WO 92-14473), for example, provides a suspension preparation containing Tipredane as the main drug as the pharmaceutical preparation for treatment of allergic rhinitis.
  • Helzner et al. (WO 97-01337) provides a pharmaceutical preparation comprising an antihistaminic drug, a steroid and water as the pharmaceutical preparation for treatment of allergic rhinitis.
  • Nagata et al. Japanese Unexamined Patent Publication (Kokai) No. 63 (1988)-303931
  • Ohwaki et al. Japanese Unexamined Patent Publication (Kokai) No.
  • 60 (1985)-123426 provides a method of applying to the nasal cavity a solution of secretin having an osmotic pressure ratio of 1 to 5 (an osmotic pressure of 290-1450 mOsm) and a pH of 2 to 5 as a method for enabling quick absorption of secretin through the nasal mucosa to blood circulation.
  • Awatsu et al. provides a method of applying to the nasal mucosa a pharmaceutical solution to which polyoxyethylene 9-laurylether was added as an absorption enhancer as a method for enabling efficient absorption of a granulocyte colony-stimulating factor through the nasal mucosa to blood circulation.
  • Ciclesonide is a newly generated lipophilic corticoid. Due to its bioactivity, a commercially available ciclesonide contained pharmaceutical preparation for topical or systemic diseases is expected.
  • a ciclesonide contained pharmaceutical preparation for application to the mucosa that allows the transport of an adequate amount of ciclesonide through the mucosa to the submucosa or the blood after the application to the mucosa.
  • the object of the present invention is to provide a pharmaceutical composition for application to the mucosa, that has efficient and high ciclesonide permeability through the mucosa to the submucosa or the blood when applied to the mucosa.
  • the present inventors After intensive studies to attain the above first object, the present inventors have found that it is possible to provide a ciclesonide contained pharmaceutical preparation for application to the mucosa that is superior over conventional liquid composition due to efficient and high permeability through the mucosa to the submucosa or the blood, by formulating ciclesonide that contains a water-insoluble and/or water-low soluble substance and that has an osmotic pressure of less than 290 mOsm, and thereby have reached the present invention.
  • the present invention provides an aqueous pharmaceutical composition for application to the mucosa comprising one or more water-insoluble substance and/or water-low soluble substance and ciclesonide, and having an osmotic pressure of less than 290 mOsm.
  • the composition is a pharmaceutical composition for application to the mucosa that is superior over conventional pharmaceutical compositions for application to the mucosa, due to markedly efficient and high ciclesonide permeability to the submucosa or the blood at the mucosa.
  • the water-insoluble or water-low soluble substance may be any substance, and preferred examples include celluloses and more preferably crystalline celluloses.
  • the concentration of the water-insoluble and/or water-low soluble substance, that is present as solid particles in an aqueous medium in the first aspect of the present invention is preferably 0.3% w/w or greater relative to the total amount of the preparation, and more preferably 1% to 10% w/w.
  • the water-insoluble or water-low soluble substance that is present as solid particles in an aqueous medium is homogeneously dispersed in the aqueous medium.
  • a water-soluble polymer is further added to the composition.
  • alginic acid, propylene glycol, pectin, low methoxyl pectin, guar gum, gum arabic, carrageenan, methyl cellulose, carboxymethyl cellulose sodium, xanthan gum, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, and the like can be mentioned, and preferably carboxymethyl cellulose sodium, xanthan gum, and hydroxypropyl cellulose can be mentioned.
  • crystalline cellulose carmellose sodium that is a mixture of carboxymethyl cellulose sodium and crystalline cellulose.
  • concentration of these water-soluble polymers, when added, is 1% w/w to 30% w/w relative to the water-insoluble and/or water-low soluble substance.
  • the osmotic pressure of the pharmaceutical preparation is less than 290 mOsm, and preferably it is 150 mOsm or lower, more preferably 60 mOsm or lower, more preferably 30 mOsm or lower, and most preferably 10 mOsm or lower.
  • a substance for controlling osmotic pressure osmotic pressure-controlling agent
  • osmotic pressure-controlling agent any substance can be used.
  • Specific examples include salts such as sodium chloride, and water-soluble sugars such as glucose, and among them salts such as sodium chloride are preferred.
  • a known surfactant can be added and specific examples include polysorbate 80, glycerin monostearate, polyoxyl stearate, Lauromacrogol, sorbitan oleate, sucrose fatty acid esters.
  • the amount of ciclesonide for use in the present invention is a therapeutically effective amount and can be determined depending on the type and the degree of the disease, the age and the weight of the patient, and the like. It is usually from the same to 20 times as much as the amount of each drug commonly used for injection, more preferably from the same to 10 times as much.
  • the concentration of ciclesonide of the present invention is preferably 0.01% w/w to 1% w/w relative to the total amount of the pharmaceutical preparation, and most preferably 0.05% w/w to 0.5% w/w.
  • a known antiseptic, a pH controlling agent, a preservative, a buffer, a colorant, a smell corrigent, and the like may be added, as desired.
  • benzalkonium chloride as the antiseptic hydrochloric acid as the pH controlling agent, ascorbic acid as the preservative, citric acid and salts thereof as the buffer, Red No. 2 as the colorant, menthol as the smell corrigent may be mentioned.
  • the mucosa to which the present invention is applied may be any mucosa. Specific examples include intestinal mucosa, gastric mucosa, nasal mucosa, tracheal/bronchial/pulmonary mucosa, mucosa of oral cavity, rectal mucosa, vaginal mucosa, and the like, and nasal mucosa is most preferred.
  • composition of the present invention may be formulated in a dosage form suitable for administration as a pharmaceutical preparation. It may contain an indirect dosage form such as an oral formulation for administration to the gastric and intestinal mucosa.
  • the composition of the present invention may be filled in a gastric or enteric capsule, for example, and the composition is exposed at the desired site of mucosa.
  • the present invention when given to the rectal mucosa, may be filled in a capsule in a unit dosage form, which is administered as a suppository.
  • the composition of the present invention When given to the oral mucosa, nasal mucosa, or vaginal mucosa, the composition of the present invention may be filled in a spray-type container, a fixed amount of which is sprayed to the oral cavity, nose, or vagina.
  • the present invention When given to the tracheal/bronchial/pulmonary mucosa, the present invention may be filled to an inhalation-type container, which is allowed to be inhaled into the trachea, bronchus, or lung.
  • Ciclesonide was obtained from Byk Gulden Lomberg Chemische Fabrik GmbH, crystalline cellulose carmellose sodium, AvicelTM RC-591NF, was manufactured by Asahi Chemical Industry, Co., Ltd., benzalkonium chloride was from Nakalai Tesque, glucose was from Wako Pure Chemicals.
  • composition No. 1 for application to the mucosa comprising the components described in the following Table 1 was prepared.
  • osmotic pressure was measured using the Micro-Osmometer Model 3MO from Advance Instruments, Inc. The result is shown in Table 1.
  • composition No. 1 for application to the nasal mucosa was sprayed to the unilateral nasal cavity of rabbits (Japanese White, male, weighing 3 kg) using a commercially available suspension device. At 5, 15 and 30 minutes after the administration, the mucus flown from the nasal cavity to the esophaguswere collected and the ciclesonide concentrations of them were determined by HPLC.
  • the clearance amount of ciclesonide from the nasal cavity to the esophagus was calculated by the flown mucus amount and their ciclesonide concentrations. Then the residual ciclesonide amount was calculated by administered ciclesonide amount and collected ciclesonide amount. The mean values of five rabbits are shown in Table 1.
  • composition No. 2 for application to the mucosa comprising the components described in the following Table 2 was prepared.
  • osmotic pressure was measured using the Micro-Osmometer Model 3MO from Advance Instruments, Inc. The result is shown in Table 2.
  • composition No. 2 for application to the nasal mucosa was sprayed to the unilateral nasal cavity of rabbits (Japanese White, male, weighing 3 kg) using a commercially available suspension device. At 5, 15 and 30 minutes after the administration, the mucus flown from the nasal cavity to the esophagus were collected and the ciclesonide concentrations of them were determined by HPLC.
  • the clearance amount of ciclesonide from the nasal cavity to the esophagus was calculated by the flown mucus amount and their ciclesonide concentrations. Then the residual ciclesonide amount was calculated by administered ciclesonide amount and collected ciclesonide amount. The mean values of five rabbits are shown in Table 2.
  • the clearance amount of ciclesonide contained composition for application to the mucosa dramatically increased with higher osmotic pressure.
  • the clearance amount of ciclesonide was 2.5-fold as much as that of Composition No. 1 (5 mOsm) and Composition No. 1 (5 mOsm) the residual ciclesonide amount was 2-fold as much as that of Composition No. 2 (330 mOsm).
  • Enhanced ciclesonide retentivity leaves a large amount of residual ciclesonide on the mucus, and it makes gradient of ciclesonide concentration around the mucosa.
  • the ciclesonide permeability to the submucosa and the blood at the mucosa is enhanced and this state is retained.
  • the present invention provides a pharmaceutical composition for application to the mucosa, that has efficient and high ciclesonide permeability through the mucosa to the submucosa or the blood when applied to the mucosa.
  • the present invention is extremely useful in terms of therapeutic and economic effects for ciclesonide therapies that employ application to the mucosa.

Abstract

The present invention provides a pharmaceutical composition for application to the mucosa to be used in drug therapy comprising a water-insoluble and/or water-low soluble substance, ciclesonide, and an aqueous medium, and having an osmotic pressure of less than 290 mOsm. This composition is superior over conventional pharmaceutical compositions for application to the mucosa, due to efficient and high ciclesonide retentivity and permeability to the submucosa or the blood at the mucosa.

Description

This application is a 371 of PCT/JP00/07350, filed on Oct. 20, 2000.
TECHNICAL FIELD
The present invention relates to a pharmaceutical composition for application to the mucosa to be used in drug therapy comprising a water-insoluble and/or water-low soluble substance, ciclesonide, and an aqueous medium, and having an osmotic pressure of less than 290 mOsm. More specifically, the present invention relates to a pharmaceutical composition for application to the mucosa comprising a water-insoluble and/or water-low soluble substance, ciclesonide, and an aqueous medium, and having an osmotic pressure of less than 290 mOsm, that is superior to conventional pharmaceutical compositions for application to the mucosa, due to ciclesonide retentivity and high ciclesonide permeability to the submucosa and the blood at the mucosa.
BACKGROUND ART
Application to the mucosa as a method of drug therapy has been recognized as a useful means of medication for such reasons as (1) it permits direct application to the affected area for diseases of local areas such as nasal mucosa, oral mucosa, and vaginal mucosa, (2) its immediate effects for systemic diseases can be expected as in the case of a nasal spray to the nasal mucosa and a suppository to the rectal mucosa, and (3) its application is easy compared to injection, as represented by an oral drug targeted at the intestinal mucosa, and the like. For example, pharmaceutical preparations for application to the mucosa have already been commercially available due to reason (1) in the case of nasal sprays for treatment of allergic rhinitis, and due to reason (2) in the case of suppositories to alleviate pain.
As pharmaceutical preparations for local mucus diseases, Saunders et al., (WO 92-14473), for example, provides a suspension preparation containing Tipredane as the main drug as the pharmaceutical preparation for treatment of allergic rhinitis. Also, Helzner et al., (WO 97-01337) provides a pharmaceutical preparation comprising an antihistaminic drug, a steroid and water as the pharmaceutical preparation for treatment of allergic rhinitis.
As the pharmaceutical preparations for systemic diseases, several methods have been provided that enhance the absorption of drugs through the mucosa. Nagata et al. (Japanese Unexamined Patent Publication (Kokai) No. 63 (1988)-303931), for example, provides a method of applying to the nasal cavity a growth hormone-releasing factor at the liquid form having an osmotic pressure ratio of 1 (an osmotic pressure of 290 mOsm) or lower as a method for enabling quick and efficient absorption of the a growth hormone-releasing factor through the nasal mucosa to the blood circulation. Furthermore, Ohwaki et al. (Japanese Unexamined Patent Publication (Kokai) No. 60 (1985)-123426) provides a method of applying to the nasal cavity a solution of secretin having an osmotic pressure ratio of 1 to 5 (an osmotic pressure of 290-1450 mOsm) and a pH of 2 to 5 as a method for enabling quick absorption of secretin through the nasal mucosa to blood circulation. Furthermore, Awatsu et al. (Pharm. Res. Vol. 10, No. 9, 1372-1377, 1993) provides a method of applying to the nasal mucosa a pharmaceutical solution to which polyoxyethylene 9-laurylether was added as an absorption enhancer as a method for enabling efficient absorption of a granulocyte colony-stimulating factor through the nasal mucosa to blood circulation.
Ciclesonide is a newly generated lipophilic corticoid. Due to its bioactivity, a commercially available ciclesonide contained pharmaceutical preparation for topical or systemic diseases is expected.
However, when a ciclesonide contained pharmaceutical preparation same composition as the conventional one is given to the mucosa, liquid-dripping can occur, or the pharmaceutical preparations are quickly excreted to the outside of the mucus tissue due to a mucociliary clearance function etc. before being adequately transported or permeated to the mucosa tissue. The method of using an absorption enhancer is yet to be realized because the absorption enhancer has the problem of irritating the nasal mucosa.
Thus, it is strongly desired to develop a ciclesonide contained pharmaceutical preparation for application to the mucosa, that allows the transport of an adequate amount of ciclesonide through the mucosa to the submucosa or the blood after the application to the mucosa.
DISCLOSURE OF THE INVENTION
The object of the present invention is to provide a pharmaceutical composition for application to the mucosa, that has efficient and high ciclesonide permeability through the mucosa to the submucosa or the blood when applied to the mucosa.
After intensive studies to attain the above first object, the present inventors have found that it is possible to provide a ciclesonide contained pharmaceutical preparation for application to the mucosa that is superior over conventional liquid composition due to efficient and high permeability through the mucosa to the submucosa or the blood, by formulating ciclesonide that contains a water-insoluble and/or water-low soluble substance and that has an osmotic pressure of less than 290 mOsm, and thereby have reached the present invention.
An enhanced absorption of a drug through the mucosa by controlling the osmotic pressure of a pharmaceutical preparation is disclosed in a patent to Osada or Ohwaki and has been reported in a paper by Awazu et al. (Pharm. Res. Vol. 10, No. 9, 1372-1377, 1993). However, these phenomena are only observed in aqueous solution preparations that do not contain a water-insoluble and/or water-low soluble substance, and thereby are essentially different from the ciclesonide contained pharmaceutical preparation of the present invention in which the inclusion of a water-insoluble and/or water-low soluble substance is essential. Furthermore, it has been shown in Osada's patent that absorption through the rat nasal mucosa of growth hormone releasing factor is higher when the preparation has an osmotic pressure ratio of 1 (osmotic pressure of 290 mOsm) or lower, and in Ohwaki's patent it is higher when secretin has an osmotic pressure ratio of 1 (osmotic pressure of 290 mOsm) or greater, and in Awazu's patent the absorption of granulocyte colony-stimulating factor is higher when the preparation has an osmotic pressure of 285 mOsm than 174 mOsm. So one cannot expect the fact that the ciclesonide absorption enhanced with decreasing an osmotic pressure.
The patent application by Saunders (WO 92-14473) and Helzner (WO 97-01337) described above describe pharmaceutical preparations containing a water-insoluble and/or water-low soluble substance. However, Saunders' patent application (WO 92-11473) makes no description of osmotic pressure of pharmaceutical preparations in general, in its claim, and merely describes in the specification that isotonicity is preferred, and Helzner's patent application makes no description of osmotic pressure of pharmaceutical preparations in general, and merely describes in the specification that the addition of an isotonic agent is preferred. From these patents, therefore, one cannot expect a drastic enhancement in the ciclesonide absorption at low osmotic pressures.
It is surprising therefore that the effect of enhancing the ciclesonide absorption at lower osmotic pressure through the mucosa is drastic when a water-insoluble or water-low soluble substance is coexistent.
Thus, the present invention provides an aqueous pharmaceutical composition for application to the mucosa comprising one or more water-insoluble substance and/or water-low soluble substance and ciclesonide, and having an osmotic pressure of less than 290 mOsm. The composition is a pharmaceutical composition for application to the mucosa that is superior over conventional pharmaceutical compositions for application to the mucosa, due to markedly efficient and high ciclesonide permeability to the submucosa or the blood at the mucosa.
EMBODIMENTS FOR CARRYING OUT THE INVENTION
In the present invention, the water-insoluble or water-low soluble substance may be any substance, and preferred examples include celluloses and more preferably crystalline celluloses.
The concentration of the water-insoluble and/or water-low soluble substance, that is present as solid particles in an aqueous medium in the first aspect of the present invention, is preferably 0.3% w/w or greater relative to the total amount of the preparation, and more preferably 1% to 10% w/w.
In any of the aspects of the present invention, preferably the water-insoluble or water-low soluble substance that is present as solid particles in an aqueous medium is homogeneously dispersed in the aqueous medium.
In any of the aspects of the present invention, preferably a water-soluble polymer is further added to the composition. Specifically, alginic acid, propylene glycol, pectin, low methoxyl pectin, guar gum, gum arabic, carrageenan, methyl cellulose, carboxymethyl cellulose sodium, xanthan gum, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, and the like can be mentioned, and preferably carboxymethyl cellulose sodium, xanthan gum, and hydroxypropyl cellulose can be mentioned. In addition, as preferred combinations of a water-soluble polymers and water-insoluble and/or water-low soluble substance, there can be mentioned crystalline cellulose carmellose sodium that is a mixture of carboxymethyl cellulose sodium and crystalline cellulose. Preferably the concentration of these water-soluble polymers, when added, is 1% w/w to 30% w/w relative to the water-insoluble and/or water-low soluble substance.
It is an essential requirement in the first aspect of the present invention that the osmotic pressure of the pharmaceutical preparation is less than 290 mOsm, and preferably it is 150 mOsm or lower, more preferably 60 mOsm or lower, more preferably 30 mOsm or lower, and most preferably 10 mOsm or lower.
In the present invention, the addition of a substance for controlling osmotic pressure (osmotic pressure-controlling agent) is not particularly required, but when it is added any substance can be used. Specific examples include salts such as sodium chloride, and water-soluble sugars such as glucose, and among them salts such as sodium chloride are preferred.
In the present invention, a known surfactant can be added and specific examples include polysorbate 80, glycerin monostearate, polyoxyl stearate, Lauromacrogol, sorbitan oleate, sucrose fatty acid esters.
The amount of ciclesonide for use in the present invention is a therapeutically effective amount and can be determined depending on the type and the degree of the disease, the age and the weight of the patient, and the like. It is usually from the same to 20 times as much as the amount of each drug commonly used for injection, more preferably from the same to 10 times as much.
The concentration of ciclesonide of the present invention is preferably 0.01% w/w to 1% w/w relative to the total amount of the pharmaceutical preparation, and most preferably 0.05% w/w to 0.5% w/w.
In order to improve the physical properties, appearances, or smells of the composition of the present invention, a known antiseptic, a pH controlling agent, a preservative, a buffer, a colorant, a smell corrigent, and the like may be added, as desired. For example, benzalkonium chloride as the antiseptic, hydrochloric acid as the pH controlling agent, ascorbic acid as the preservative, citric acid and salts thereof as the buffer, Red No. 2 as the colorant, menthol as the smell corrigent may be mentioned.
The mucosa to which the present invention is applied may be any mucosa. Specific examples include intestinal mucosa, gastric mucosa, nasal mucosa, tracheal/bronchial/pulmonary mucosa, mucosa of oral cavity, rectal mucosa, vaginal mucosa, and the like, and nasal mucosa is most preferred.
The composition of the present invention may be formulated in a dosage form suitable for administration as a pharmaceutical preparation. It may contain an indirect dosage form such as an oral formulation for administration to the gastric and intestinal mucosa. In this case, the composition of the present invention may be filled in a gastric or enteric capsule, for example, and the composition is exposed at the desired site of mucosa. As another dosage form, when given to the rectal mucosa, the present invention may be filled in a capsule in a unit dosage form, which is administered as a suppository. When given to the oral mucosa, nasal mucosa, or vaginal mucosa, the composition of the present invention may be filled in a spray-type container, a fixed amount of which is sprayed to the oral cavity, nose, or vagina. When given to the tracheal/bronchial/pulmonary mucosa, the present invention may be filled to an inhalation-type container, which is allowed to be inhaled into the trachea, bronchus, or lung.
EXAMPLES
The present invention will now be explained with reference to the following examples.
Ciclesonide was obtained from Byk Gulden Lomberg Chemische Fabrik GmbH, crystalline cellulose carmellose sodium, Avicel™ RC-591NF, was manufactured by Asahi Chemical Industry, Co., Ltd., benzalkonium chloride was from Nakalai Tesque, glucose was from Wako Pure Chemicals.
Example 1
A ciclesonide contained composition No. 1 for application to the mucosa comprising the components described in the following Table 1 was prepared. For this pharmaceutical preparation, osmotic pressure was measured using the Micro-Osmometer Model 3MO from Advance Instruments, Inc. The result is shown in Table 1.
One hundred μl of the composition No. 1 for application to the nasal mucosa was sprayed to the unilateral nasal cavity of rabbits (Japanese White, male, weighing 3 kg) using a commercially available suspension device. At 5, 15 and 30 minutes after the administration, the mucus flown from the nasal cavity to the esophaguswere collected and the ciclesonide concentrations of them were determined by HPLC.
Then, 30 minutes after the administration, residual ciclesonide in the nasal cavity were washed with ethanol and the ciclesonide concentrations of washing fluid were determined by HPLC.
The clearance amount of ciclesonide from the nasal cavity to the esophagus was calculated by the flown mucus amount and their ciclesonide concentrations. Then the residual ciclesonide amount was calculated by administered ciclesonide amount and collected ciclesonide amount. The mean values of five rabbits are shown in Table 1.
TABLE 1
Clearance Res-
Osmotic amount (%) idual
pressure 5 15 30 amount
No. Composition (mOsm) min min min (%)
1 Ciclesonide: 0.2% w/w 5 6.75 12.97 20.41 39.81
Crystalline cellulose
carmellose sodium:
1.7% w/w
Benzalkonium chloride:
0.02% w/w
Comparative Example 1
A ciclesonide contained composition No. 2 for application to the mucosa comprising the components described in the following Table 2 was prepared. For this pharmaceutical preparation, osmotic pressure was measured using the Micro-Osmometer Model 3MO from Advance Instruments, Inc. The result is shown in Table 2.
One hundred μl of the composition No. 2 for application to the nasal mucosa was sprayed to the unilateral nasal cavity of rabbits (Japanese White, male, weighing 3 kg) using a commercially available suspension device. At 5, 15 and 30 minutes after the administration, the mucus flown from the nasal cavity to the esophagus were collected and the ciclesonide concentrations of them were determined by HPLC.
Then, 30 minutes after the administration, residual ciclesonide in the nasal cavity were washed with ethanol and the ciclesonide concentrations of washing fluid were determined by HPLC.
The clearance amount of ciclesonide from the nasal cavity to the esophagus was calculated by the flown mucus amount and their ciclesonide concentrations. Then the residual ciclesonide amount was calculated by administered ciclesonide amount and collected ciclesonide amount. The mean values of five rabbits are shown in Table 2.
TABLE 2
Clearance Res-
Osmotic amount (%) idual
pressure 5 15 30 amount
No. Composition (mOsm) min min min (%)
2 Ciclesonide: 0.2% w/w 330 39.85 51.11 55.08 17.76
Crystalline cellulose
carmellose sodium:
1.7% w/w
Benzalkonium chloride:
0.02% w/w
Glucose: 5.7% w/w
The clearance amount of ciclesonide contained composition for application to the mucosa dramatically increased with higher osmotic pressure. At thirty minutes after administration of Composition No. 2 (330 mOsm) the clearance amount of ciclesonide was 2.5-fold as much as that of Composition No. 1 (5 mOsm) and Composition No. 1 (5 mOsm) the residual ciclesonide amount was 2-fold as much as that of Composition No. 2 (330 mOsm). These results show that the ciclesonide retentivity was enhanced by lowering the osmotic pressure from 330 mOsm to 5 mOsm.
Enhanced ciclesonide retentivity leaves a large amount of residual ciclesonide on the mucus, and it makes gradient of ciclesonide concentration around the mucosa. Thus the ciclesonide permeability to the submucosa and the blood at the mucosa is enhanced and this state is retained.
INDUSTRIAL APPLICABILITY
Thus, the present invention provides a pharmaceutical composition for application to the mucosa, that has efficient and high ciclesonide permeability through the mucosa to the submucosa or the blood when applied to the mucosa.
By using such a composition of the present invention for application to the mucosa, effects equal to or greater than those obtained with the same composition as the conventional compositions can be obtained even at smaller doses or lower administration frequencies than the conventional methods. This can lead to reduction in side effects.
Thus, the present invention is extremely useful in terms of therapeutic and economic effects for ciclesonide therapies that employ application to the mucosa.

Claims (22)

What is claimed is:
1. An aqueous pharmaceutical composition for application to the mucosa, comprising one or more water-insoluble and/or water-low soluble substance, and ciclesonide, and having an osmotic pressure of 150 mOsm or less.
2. The pharmaceutical composition for application to the mucosa according to claim 1, wherein said osmotic pressure is 60 mOsm or less.
3. The pharmaceutical composition for application to the mucosa according to claim 1, wherein said osmotic pressure is 30 mOsm or less.
4. The pharmaceutical composition for application to the mucosa according to claim 1, wherein said osmotic pressure is 10 mOsm or less.
5. The pharmaceutical composition for application to the mucosa according to claim 1, further comprising an osmotic pressure-controlling agent.
6. The pharmaceutical composition for application to the mucosa according to claim 5, wherein said osmotic pressure-controlling agent is a salt.
7. The pharmaceutical composition for application to the mucosa according to claim 6, wherein said osmotic pressure-controlling agent is sodium chloride.
8. The pharmaceutical composition for application to the mucosa according to claim 5, wherein said osmotic pressure-controlling agent is a water-soluble sugar.
9. The pharmaceutical composition for application to the mucosa according to claim 8, wherein said osmotic pressure-controlling agent is glucose.
10. The pharmaceutical composition for application to the mucosa according to claim 1, wherein said water-insoluble and/or water-low soluble substance is a cellulose.
11. The pharmaceutical composition for application to the mucosa according to claim 10, wherein said cellulose is crystalline cellulose.
12. The pharmaceutical composition for application to the mucosa according to claim 1, wherein said one or more water-insoluble and/or water-low soluble substance is present as solid particles in an aqueous medium.
13. The pharmaceutical composition for application to the mucosa according to claim 1, wherein said one or more water-insoluble and/or water-low soluble substance is dispersed as solid particles in an aqueous medium.
14. The pharmaceutical composition for application to the mucosa according to claim 1, further comprising a water-soluble polymer substance.
15. The pharmaceutical composition for application to the mucosa according to claim 14, wherein said water-soluble polymer is one or more selected from the group consisting of alginic acid, propylene glycol, pectin, low methoxyl pectin guar gum, gum arabic, carrageenan, methyl cellulose, carboxymethyl cellulose sodium, xanthan gum, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose.
16. The pharmaceutical composition for application to the mucosa according to claim 14, wherein said water-soluble polymer is carboxymethyl cellulose sodium.
17. The pharmaceutical composition for application to the mucosa according to claim 14, wherein said water-soluble polymer is xanthan gum.
18. The pharmaceutical composition for application to the mucosa according to claim 15, wherein said water-soluble polymer is hydroxypropyl methyl cellulose.
19. The pharmaceutical composition for application to the mucosa according to claim 14, wherein the combination of said water-insoluble substance and water-soluble polymer is crystalline cellulose carmellose sodium.
20. The pharmaceutical composition for application to the mucosa according to claim 1, further comprising a surfactant.
21. The pharmaceutical composition for application to the mucosa according to claim 20, wherein said surfactant is polysorbate 80.
22. The pharmaceutical composition ion to the mucosa according to claim 1, mucosa is nasal mucosa.
US10/110,629 1999-10-20 2000-10-20 Ciclesonide contained pharmaceutical composition for application to mucosa Expired - Lifetime US6767901B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP11-298185 1999-10-20
JP29818599 1999-10-20
PCT/JP2000/007350 WO2001028562A1 (en) 1999-10-20 2000-10-20 Ciclesonide contained pharmaceutical composition for application to mucosa

Publications (1)

Publication Number Publication Date
US6767901B1 true US6767901B1 (en) 2004-07-27

Family

ID=17856327

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/110,629 Expired - Lifetime US6767901B1 (en) 1999-10-20 2000-10-20 Ciclesonide contained pharmaceutical composition for application to mucosa

Country Status (36)

Country Link
US (1) US6767901B1 (en)
EP (1) EP1225902B1 (en)
JP (1) JP4264211B2 (en)
KR (1) KR100722209B1 (en)
CN (2) CN1379674B (en)
AR (1) AR026072A1 (en)
AT (1) ATE285779T1 (en)
AU (1) AU781895B2 (en)
BG (1) BG65818B1 (en)
BR (1) BRPI0014878B8 (en)
CA (1) CA2388322C (en)
CO (1) CO5261494A1 (en)
CZ (1) CZ297779B6 (en)
DE (1) DE60017175T2 (en)
DK (1) DK1225902T3 (en)
EA (1) EA006015B1 (en)
ES (1) ES2234681T3 (en)
HK (2) HK1050858A1 (en)
HR (1) HRP20020346B1 (en)
HU (1) HU228893B1 (en)
IL (2) IL148691A0 (en)
ME (1) ME00567A (en)
MX (1) MXPA02003974A (en)
MY (1) MY136987A (en)
NO (1) NO327444B1 (en)
NZ (1) NZ518298A (en)
PE (1) PE20010712A1 (en)
PL (1) PL199702B1 (en)
PT (1) PT1225902E (en)
RS (1) RS50310B (en)
SI (1) SI1225902T1 (en)
SK (1) SK286196B6 (en)
TR (1) TR200200841T2 (en)
TW (1) TWI225788B (en)
WO (1) WO2001028562A1 (en)
ZA (1) ZA200203077B (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050245493A1 (en) * 2002-08-30 2005-11-03 Degenhard Marx Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
US20060025392A1 (en) * 2002-12-12 2006-02-02 Altana Pharma Ag Combination medicament
US20070025923A1 (en) * 2003-09-16 2007-02-01 Altana Pharma Ag Use of ciclesonide for the treatment of respiratory diseases
US20070134165A1 (en) * 2004-04-20 2007-06-14 Altana Pharma Ag Use of Ciclesonide for the Treatment of Respiratory Disease in a Smoking Patient
US20080027034A1 (en) * 2004-09-10 2008-01-31 Shah Tushar P Ciclesonide and Syk Inhibitor Combination and Method of Use Thereof
WO2011135585A2 (en) 2010-04-28 2011-11-03 Cadila Healthcare Limited Aqueous pharmaceutical solution of ciclesonide
US8228725B2 (en) 2002-07-08 2012-07-24 Micron Technology, Inc. Memory utilizing oxide nanolaminates
US8383611B1 (en) 1999-10-20 2013-02-26 Nycomed Gmbh Ciclesonide containing aqueous pharmaceutical composition

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR026072A1 (en) * 1999-10-20 2002-12-26 Nycomed Gmbh PHARMACEUTICAL COMPOSITION CONTAINING CICLESONIDE FOR MUCOSA APPLICATION
CN100366256C (en) * 2002-07-02 2008-02-06 奥坦纳医药公司 Ciclesonide-containing sterile aqueous suspension
KR20050025637A (en) * 2002-07-26 2005-03-14 에프엠씨 코포레이션 Production of microcrystalline cellulose
MY143936A (en) 2003-03-27 2011-07-29 Nycomed Gmbh Process for preparing crystalline ciclesonide with defined particle size
PE20050941A1 (en) * 2003-12-16 2005-11-08 Nycomed Gmbh AQUEOUS CYCLESOUND SUSPENSIONS FOR MISTING
EP1645266A1 (en) * 2004-10-08 2006-04-12 Hisamitsu Medical Co., Ltd. Aqueous suspension for nasal drops
WO2009114192A2 (en) * 2008-03-14 2009-09-17 Cephalon, Inc. Enhanced transmucosal composition and dosage form

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014473A1 (en) 1991-02-23 1992-09-03 Fisons Ag Steroid formulations
WO1997001337A1 (en) 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal steroids
WO1998052542A1 (en) 1997-05-21 1998-11-26 Minnesota Mining And Manufacturing Company Medicinal aerosol products
WO1999025359A1 (en) 1997-11-14 1999-05-27 Astrazeneca Ab New composition of matter
WO1999037286A1 (en) 1998-01-22 1999-07-29 Santen Pharmaceutical Co., Ltd. Fluorometholone suspension eye drops
WO1999047144A1 (en) 1998-03-17 1999-09-23 Pharmalink Basläkemedel Ab Method and means for treating glomerulonephritis
US20030008019A1 (en) 1998-04-21 2003-01-09 Teijin Limited Pharmaceutical composition for application to mucosa

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63303931A (en) * 1987-06-05 1988-12-12 Sumitomo Pharmaceut Co Ltd Drug preparation for transnasal administration having growth hormone releasing activity
AR026072A1 (en) * 1999-10-20 2002-12-26 Nycomed Gmbh PHARMACEUTICAL COMPOSITION CONTAINING CICLESONIDE FOR MUCOSA APPLICATION

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014473A1 (en) 1991-02-23 1992-09-03 Fisons Ag Steroid formulations
WO1997001337A1 (en) 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal steroids
WO1998052542A1 (en) 1997-05-21 1998-11-26 Minnesota Mining And Manufacturing Company Medicinal aerosol products
WO1999025359A1 (en) 1997-11-14 1999-05-27 Astrazeneca Ab New composition of matter
WO1999037286A1 (en) 1998-01-22 1999-07-29 Santen Pharmaceutical Co., Ltd. Fluorometholone suspension eye drops
WO1999047144A1 (en) 1998-03-17 1999-09-23 Pharmalink Basläkemedel Ab Method and means for treating glomerulonephritis
US20030008019A1 (en) 1998-04-21 2003-01-09 Teijin Limited Pharmaceutical composition for application to mucosa

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Japanese unexamined Patent Publication 60-123426, Jul. 2, 1985, Abstract.
Japanese unexamined Patent Publication 63-303931, Dec. 12, 1998 Abstract.
Machida, M., et al. "Absorption of Recombinant Human Granulocyte Colony-Stimulating Factor (rhG-CSF) from Rat Nasal Mucosa", Pharmaceutical Research, vol. 10, No. 9, 1993.
Machida, Minoru, et al., "Absorption of Recombinant Human Granulocyte Colony-Stimulating Factor (rhG-CSF) from Rat Nasal Mucosa". Pharmaceutical Research, vol. 10, No. 9, 1993, pp. 1372-1377.

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383611B1 (en) 1999-10-20 2013-02-26 Nycomed Gmbh Ciclesonide containing aqueous pharmaceutical composition
US8228725B2 (en) 2002-07-08 2012-07-24 Micron Technology, Inc. Memory utilizing oxide nanolaminates
US20110092471A1 (en) * 2002-08-30 2011-04-21 Nycomed Gmbh Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
US8486923B2 (en) 2002-08-30 2013-07-16 Takeda Gmbh Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
US20050245493A1 (en) * 2002-08-30 2005-11-03 Degenhard Marx Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
US7879832B2 (en) 2002-08-30 2011-02-01 Nycomed Gmbh Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
US8258124B2 (en) 2002-12-12 2012-09-04 Nycomed Gmbh Combination medicament
US20110086827A1 (en) * 2002-12-12 2011-04-14 Nycomed Gmbh Combination medicament
US7879833B2 (en) 2002-12-12 2011-02-01 Nycomed Gmbh Combination medicament
US20060025392A1 (en) * 2002-12-12 2006-02-02 Altana Pharma Ag Combination medicament
US8371292B2 (en) 2003-09-16 2013-02-12 Nycomed Gmbh Use of ciclesonide for the treatment of respiratory diseases
US20070025923A1 (en) * 2003-09-16 2007-02-01 Altana Pharma Ag Use of ciclesonide for the treatment of respiratory diseases
US20070134165A1 (en) * 2004-04-20 2007-06-14 Altana Pharma Ag Use of Ciclesonide for the Treatment of Respiratory Disease in a Smoking Patient
US20080027034A1 (en) * 2004-09-10 2008-01-31 Shah Tushar P Ciclesonide and Syk Inhibitor Combination and Method of Use Thereof
WO2011135585A2 (en) 2010-04-28 2011-11-03 Cadila Healthcare Limited Aqueous pharmaceutical solution of ciclesonide
WO2011135585A3 (en) * 2010-04-28 2012-01-26 Cadila Healthcare Limited Aqueous pharmaceutical solution of ciclesonide

Also Published As

Publication number Publication date
ATE285779T1 (en) 2005-01-15
NO20021898L (en) 2002-04-22
ME00567B (en) 2011-12-20
EP1225902A1 (en) 2002-07-31
JP4264211B2 (en) 2009-05-13
PL199702B1 (en) 2008-10-31
KR100722209B1 (en) 2007-05-29
CN101869570A (en) 2010-10-27
ZA200203077B (en) 2003-02-26
BG106512A (en) 2002-12-29
CN1379674A (en) 2002-11-13
DK1225902T3 (en) 2005-05-02
HRP20020346A2 (en) 2004-02-29
PL356191A1 (en) 2004-06-14
WO2001028562A1 (en) 2001-04-26
HK1050858A1 (en) 2003-07-11
YU28002A (en) 2004-11-25
HRP20020346B1 (en) 2011-06-30
PE20010712A1 (en) 2001-07-12
DE60017175T2 (en) 2005-12-29
ME00567A (en) 2011-12-20
ES2234681T3 (en) 2005-07-01
CZ20021238A3 (en) 2002-07-17
HU228893B1 (en) 2013-06-28
AU781895B2 (en) 2005-06-23
CN101869570B (en) 2012-10-10
MY136987A (en) 2008-12-31
AR026072A1 (en) 2002-12-26
CA2388322A1 (en) 2001-04-26
CZ297779B6 (en) 2007-03-28
BG65818B1 (en) 2010-01-29
JP2003512329A (en) 2003-04-02
NO327444B1 (en) 2009-06-29
AU7953100A (en) 2001-04-30
SI1225902T1 (en) 2005-06-30
CA2388322C (en) 2007-09-18
PT1225902E (en) 2005-05-31
HUP0203339A2 (en) 2003-02-28
BRPI0014878B1 (en) 2015-08-11
EA006015B1 (en) 2005-08-25
TR200200841T2 (en) 2002-07-22
BRPI0014878B8 (en) 2021-05-25
SK6922002A3 (en) 2002-09-10
EA200200375A1 (en) 2002-10-31
BR0014878A (en) 2002-06-11
HUP0203339A3 (en) 2004-07-28
IL148691A0 (en) 2002-09-12
KR20020059627A (en) 2002-07-13
NZ518298A (en) 2003-11-28
SK286196B6 (en) 2008-05-06
MXPA02003974A (en) 2003-09-25
IL148691A (en) 2006-12-10
DE60017175D1 (en) 2005-02-03
EP1225902B1 (en) 2004-12-29
HK1149719A1 (en) 2011-10-14
CO5261494A1 (en) 2003-03-31
RS50310B (en) 2009-09-08
NO20021898D0 (en) 2002-04-22
CN1379674B (en) 2014-10-29
TWI225788B (en) 2005-01-01

Similar Documents

Publication Publication Date Title
EP0998916B1 (en) Medicinal compositions for application to mucosa
US6767901B1 (en) Ciclesonide contained pharmaceutical composition for application to mucosa
JP2012001558A (en) Novel combination of loteprednol and antihistamine
CN101757625A (en) Nasal pharmaceutical composition of cyclodextrin inclusion cortin and H1 receptor antagonist
MXPA99011639A (en) Medicinal compositions for application to mucosa

Legal Events

Date Code Title Description
AS Assignment

Owner name: BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NAGANO, ATSUHIRO;NISHIBE, YOSHIHISA;TAKANASHI, KAZUYA;REEL/FRAME:013085/0968;SIGNING DATES FROM 20020404 TO 20020408

AS Assignment

Owner name: ALTANA PHARMA AG, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH;REEL/FRAME:013169/0604

Effective date: 20020701

AS Assignment

Owner name: ALTANA PHARMA AG, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH;REEL/FRAME:013751/0522

Effective date: 20020701

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
AS Assignment

Owner name: NYCOMED GMBH, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:ALTANA PHARMA AG;REEL/FRAME:019781/0225

Effective date: 20070614

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

AS Assignment

Owner name: TAKEDA GMBH, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:NYCOMED GMBH;REEL/FRAME:030091/0737

Effective date: 20121114

FPAY Fee payment

Year of fee payment: 12

AS Assignment

Owner name: NYCOMED ASSET MANAGEMENT GMBH, GERMANY

Free format text: MERGER;ASSIGNOR:TAKEDA GMBH;REEL/FRAME:037820/0324

Effective date: 20121025

Owner name: NYCOMED GERMANY HOLDING GMBH, GERMANY

Free format text: MERGER;ASSIGNOR:NYCOMED ASSET MANAGEMENT GMBH;REEL/FRAME:037820/0360

Effective date: 20141020

Owner name: TAKEDA GMBH, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:NYCOMED GERMANY HOLDING GMBH;REEL/FRAME:038020/0258

Effective date: 20141020

AS Assignment

Owner name: ASTRAZENECA AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TAKEDA GMBH;REEL/FRAME:041328/0362

Effective date: 20160429

AS Assignment

Owner name: COVIS PHARMA B.V., NETHERLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ASTRAZENECA AB;REEL/FRAME:047761/0435

Effective date: 20181204

AS Assignment

Owner name: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT, ILLINOIS

Free format text: SECURITY INTEREST;ASSIGNOR:COVIS PHARMA B.V.;REEL/FRAME:047834/0926

Effective date: 20181204

Owner name: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL A

Free format text: SECURITY INTEREST;ASSIGNOR:COVIS PHARMA B.V.;REEL/FRAME:047834/0926

Effective date: 20181204

AS Assignment

Owner name: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT, ILLINOIS

Free format text: SECURITY INTEREST;ASSIGNOR:COVIS PHARMA B.V.;REEL/FRAME:052095/0262

Effective date: 20200310

AS Assignment

Owner name: COVIS PHARMA B.V., SWITZERLAND

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT;REEL/FRAME:052142/0961

Effective date: 20200310

AS Assignment

Owner name: COVIS PHARMA GMBH, SWITZERLAND

Free format text: BUSINESS TRANSFER AND CONTRIBUTION AGREEMENT;ASSIGNOR:COVIS PHARMA B.V.;REEL/FRAME:054793/0416

Effective date: 20201116

AS Assignment

Owner name: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT, ILLINOIS

Free format text: SECURITY INTEREST;ASSIGNOR:COVIS PHARMA GMBH;REEL/FRAME:055354/0063

Effective date: 20210210

AS Assignment

Owner name: COVIS PHARMA B.V., SWITZERLAND

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CAPITAL ONE, NATIONAL ASSOCIATION;REEL/FRAME:059043/0239

Effective date: 20220104

Owner name: COVIS PHARMA GMBH, SWITZERLAND

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CAPITAL ONE, NATIONAL ASSOCIATION;REEL/FRAME:059043/0226

Effective date: 20220104